Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

Hui, Rina; ÖZGÜROĞLU, MUSTAFA; Villegas, Augusto; Daniel, Davey; Vicente, David; Murakami, Shuji; Yokoi, Takashi; Chiappori, Alberto; Lee, Ki; de Wit, Maike; Cho, Byoung; Gray, Jhanelle; Ryden, Anna; Viviers, Louis; Poole, Lynne; Zhang, Yiduo; Dennis, Phillip; Antonia, Scott

doi:10.1016/s1470-2045(19)30519-4

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

Hui R., ÖZGÜROĞLU M., Villegas A., Daniel D., Vicente D., Murakami S., ...Daha Fazla

LANCET ONCOLOGY, cilt.20, sa.12, ss.1670-1680, 2019 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 20 Sayı: 12
Basım Tarihi: 2019
Doi Numarası: 10.1016/s1470-2045(19)30519-4
Dergi Adı: LANCET ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1670-1680
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background In the ongoing, phase 3 PACIFIC trial, durvalumab improved the primary endpoints of progression-free survival and overall survival compared with that for placebo, with similar safety, in patients with unresectable, stage III non-small-cell lung cancer. In this analysis, we aimed to evaluate one of the secondary endpoints, patient-reported outcomes (PROs).